logo
I covered the L.A. fires in the Palisades. So I had my blood tested for lead

I covered the L.A. fires in the Palisades. So I had my blood tested for lead

Yahoo02-07-2025
I watched my blood snake through the tube stuck into my arm as I sat under a canopy erected by the Los Angeles County Department of Public Health at an Altadena church.
Four months prior — almost to the hour — I stepped out of my car in Pacific Palisades to wailing sirens, raining ash and fleeing people.
Now, like hundreds of others, I desperately wanted to know: Had lead once locked away in the homes of the Palisades and Altadena seeped into my bloodstream? And, if so, how much now sat in the vial in the hands of Jessica Segura, a nurse with the Department of Public Health?
Tania Rysinski took my chair after me. She had evacuated from Pasadena and, after a trying remediation process, had moved back home with her husband and 3-year-old daughter. I asked what brought her to the Eaton fire resource fair.
'I also worry,' she told me. 'My daughter is the one that we worry about the most.'
Despite hours of reading about and discussing remediation and health hazards with friends and family, Rysinski found little certainty that her family was safe. I shared her apprehension.
Alongside other health and environment reporters at The Times, I've read thick scientific studies, reviewed reams of data and interviewed dozens of experts to understand what dangerous compounds, transported by wind and smoke, had laced our water systems, settled into homes and embedded themselves in the soil and our bodies.
Even so, our reporting left me feeling mostly frustrated with my brain. Several times, after I interviewed residents in the burn areas, they would say: You've covered this in detail. Would you feel comfortable moving back here with kids?
I didn't know.
A 20-foot-tall flame staring at you through the windshield is a very tangible risk. The lead lurking in the air and soil is a different story. It is invisible and damages our bodies in complex ways. And that damage happens quietly.
Segura, the nurse, removed the tube from my arm and pressed a cotton ball to the needle prick. The results would not be a simple positive or negative, she explained. Instead, it would list the concentration in micrograms of lead per deciliter of blood. Anything over 3.5 mcg/dL requires follow-up care, according to the Centers for Disease Control and Prevention.
I could expect results within two weeks, Segura said. I asked Rysinski what her plan was if her levels were high.
'I have no idea,' she said.
Neither did I.
I, admittedly, took little precaution to protect myself from the wildfire smoke during the three days I spent in Pacific Palisades.
My brain focused on more immediate concerns: dodging downed electrical wires, plotting escape routes, jump=starting folks' cars and watching in horror as buildings erupted into flames in front of me.
Rysinski had felt the same in Pasadena. 'We were all on survival mode,' she said.
After retreating to my car, which reeked of smoke, for a brief break the morning after the fires erupted, I got a message from my editor. Like concerned friends and family who had been messaging me from the East Coast — and strangers who'd seen my reports on Instagram — the editor wanted to know what the smoke might be doing to our lungs. And were people worried?
I threw my body weight against the car door, barely managing to out-muscle the wind, and stumbled through gale-force gusts to talk to folks. At a haphazardly parked SUV, Amber Vanderbilt rolled down the window.
'I know this isn't on the top of most people's minds,' I said, 'but I'm curious how you or the people you know have been dealing with the air quality. Has that been a concern for you?'
'No,' she said with a chuckle. 'I see that it's on the news too, which is really funny.' In fact, the discourse had frustrated her enough that she recalled yelling at the TV newscast, 'No one cares! Show me where the fire perimeter is! Tell me where the wind is going!'
I chuckled with her. I too did not care.
Then, I started looking at the data.
On Jan. 8, an air quality sensor in Chinatown had read fine particulate matter at a concentration over 13 times the federal daily limit — the number that had prompted my team to elicit my interview with Vanderbilt.
Amid the scattered, ad hoc testing efforts that followed, one emerged as a leader: the LA Fire HEALTH Study, or the Los Angeles Fire Human Exposure and Long-Term Health Study. Scientists from eight research institutions had banded together with some private funding to, ambitiously, study the health effects of the fires over the course of a decade.
In May, I attended one of their events — supposedly a symposium, definitely a cocktail party and perhaps a fundraiser — at a home in Brentwood.
A Times photographer and I, slightly underdressed, scuttled past the valet and into the backyard. Guests began migrating to the white lawn chairs set up on the tennis court to hear the scientists speak.
The jaunty atmosphere turned tense as Palisadians struggled to make sense of the environmental crisis unfolding in front of them.
'My daughter is a surfer, Pali High student. She's only 17 years old,' one attendee said when the topic of beaches came up. 'Our family is having a really, really hard time telling what the actual truth is.'
Dr. David Eisenman, a UCLA public health professor and an avid surfer, had hit the waves that morning after carefully reviewing the nonprofit Heal the Bay's latest test results that showed no significant levels of contaminants in the water.
But the attendee pushed back.
'I know a mom who spent $6,000 of her own money to have the beach tested and she found ridiculously high levels of arsenic,' she said. 'This is where children are playing. This is insane. So, we don't know who to trust. We don't know what to do.'
The researchers sympathized with her frustration.
For almost every combination of contaminant and domain, scientists have rigorously studied the exposure risk and health impact, and, based on that, the federal and state governments have set screening levels: Any more of a particular contaminant requires additional action.
California's level for lead in residential soil is 80 milligrams per kilogram. That's the amount that, in the worst case, can raise the blood lead level of a child who routinely plays in the soil by 1 mcg/dL. A blood lead level increase in children of 5 mcg/dL corresponds to a loss of roughly 1 to 3 IQ points.
But the problem quickly gets more complicated than that.
Take the state's screening level for arsenic, for example, based on a 1-in-a-million chance of developing cancer over a lifetime of exposure. The level is 0.032 milligram per kilogram of soil. But arsenic naturally occurs in soil, typically 2 to 11 milligrams per kilogram.
When I asked the state Department of Toxic Substances Control about this, it had a shockingly morbid answer. Arsenic occurring naturally at potentially cancer-causing levels, it said, is simply 'a part of living on Earth.'
It's not hard to see why talk of contaminants leaves people frustrated and confused. That includes me, whose full-time job is to figure this stuff out.
Yet one report from the LA Fire HEALTH Study struck me as surprisingly lucid. I couldn't get it out of my head.
Dr. Kari Nadeau, a researcher with the study and professor at the Harvard T.H. Chan School of Public Health, has been collecting firefighters' blood for years. After the L.A. County wildfires, she did the same.
The results: The firefighters who battled L.A. County's urban fires had lead levels in their blood five times of those who had battled forest fires in Yosemite.
Technically, no level of lead in the blood is safe, but we all live with it in our blood. The average American's blood lead level sits around 0.8 mcg/dL.
Elevated levels in kids — above 3.5 mcg/dL, according to the CDC — can cause significant brain and nerve damage leading to slowed development and behavioral issues. Adults are less sensitive to lead, but under much higher concentrations — beyond 40 mcg/dL — the metal, which the body mistakes for calcium, can damage many organs.
When I read my colleague's coverage of Nadeau's findings in March, a thought flickered from the back of my mind: What was in my blood?
As I waited for my blood test results via snail mail, I became increasingly interested not only in what the environmental health risks of the fires are, but also how our brains process them.
Spending so much time in the data had changed me. One weekend I sat next to a campfire, and as I admired the dancing flames, I also imagined the benzene and polycyclic aromatic hydrocarbons the fire was stripping from the wood and whispering into the air for me to inhale. In my head, I recited the federal and state screening levels for airborne chemicals, like a high school student studying for a chemistry exam.
So, I called professor Wändi Bruine de Bruin, director of the Schaeffer Institute's Behavioral Science and Policy Initiative at USC and an expert on the psychology of risk assessment.
'Any situation with environmental risk can be hard to comprehend … but with the fires, it is much more complex,' she said. Stacking multiple risks with limited information while likely dealing with a lost home and uncertain future — 'it's a lot.'
To escape the helpless quest to find solace and certainty in the numbers, Bruine de Bruin recommended focusing on the most relevant data to you from trusted experts or your own testing, then shifting your focus to simple, accessible actions to limit future exposure.
Dr. Michael Crane, a leading health expert in the response to 9/11 and the following environmental disaster, agreed with Bruine de Bruin.
'It's funny, if you make a decision about it, you usually get some peace on that point,' Crane said. 'I would urge people to manage the controllable risks — the ones that are right there, in their fingers.'
As the initial shock of the terrorist attacks morphed into trauma, the very real long-term cancer risk posed by the smoke and debris began to sink in among New York's medical community. Crane recalled when an expert from the National Cancer Institute came down to talk with doctors.
'Fantastic young guy, and I mean, we basically surrounded him,' he said.
The doctors unloaded all their burning cancer questions until one finally yelled, 'Well, what do you think we should do?"
'Get them to stop smoking,' the expert bluntly replied.
Suffice to say, it did not soothe the doctors' concerns.
'He was lucky to get out of that room alive at that point,' Crane said.
Yet that one sentence, Crane believes, is a large part of why the cancer rates never reached the sky-high levels many of those doctors feared.
Since we don't have silver-bullet medical techniques to reverse the effects of exposure to all harmful contaminants, it's prudent we try to prevent another exposure and lead healthy lives. For doctors, it means staying vigilant: aware of their patients' risks and ready to act should those risks become a reality.
Crane chuckled as he recalled the seeming absurdity of the expert's cancer comment; then he turned sincere. "We're very grateful for that guy,' he said.
Ten days after my blood test, a letter from the Department of Public Health arrived. I quickly opened it.
The lead level in my blood: less than 1 mcg/dL.
Rysinski texted me a few days later to share that her results were the same.
In fact, of the 1,350 individuals concerned about their exposures from the wildfires who had partaken in the county's lead blood testing program as of May 31, only seven had levels greater than 3.5 mcg/dL. All were adults older than 40; all lead levels were under 10 mcg/dL.
Dr. Nichole Quick, chief medical advisor for the Department of Public Health, wants people to remain cautious about contamination but is pleased by the initial results of the county's lead testing program.
'The results are reassuring,' Quick told me, looking at numbers from the beginning of May.
Reassuring not that contamination isn't present — it is — but that many of us are taking the simple, manageable steps to lower our risk.
To face the often scary and seemingly insurmountable challenge of making it through our scarred landscape, we must do the little things. Wash our hands, clean the floors and keep the cigarettes away from our lips.
This story originally appeared in Los Angeles Times.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Trump Administration Blocks Funding for CDC Health Programs
Trump Administration Blocks Funding for CDC Health Programs

Wall Street Journal

timean hour ago

  • Wall Street Journal

Trump Administration Blocks Funding for CDC Health Programs

WASHINGTON—The Trump administration is blocking funding for a swath of public-health programs run by the Centers for Disease Control and Prevention, the latest flashpoint in a push by the White House to withhold money already approved by Congress. The White House Office of Management and Budget issued the directions in a footnote on an appropriations memo this past week, according to people familiar with the matter. A range of programs won't be fully funded under the freeze.

UCLA loses federal research funding in administration's ongoing fight with top universities
UCLA loses federal research funding in administration's ongoing fight with top universities

CNN

time3 hours ago

  • CNN

UCLA loses federal research funding in administration's ongoing fight with top universities

UCLA is the latest major institution of higher learning to see promised research funding snatched away by the Trump administration, the university's leader said in an open letter to students and faculty Thursday. 'This is not only a loss to the researchers who rely on critical grants,' wrote Chancellor Julio Frenk. 'It is a loss for Americans across the nation whose work, health, and future depend on the groundbreaking work we do.' Grants from the National Science Foundation and the National Institutes of Health are included in the suspensions, Frenk said, but did not provide an amount of how much funding is in peril. The Los Angeles Times reported that roughly $200 million in grants awarded to UCLA are being suspended, citing a partial list of suspended grants provided to them by a source. A spokesperson for the National Science Foundation declined to provide specific figures, saying grant awards are being suspended 'because they are not in alignment with current NSF priorities and/or programmatic goals.' 'We will not fund institutions that promote antisemitism,' said a spokesperson for the Department of Health and Human Services, which includes the National Institutes of Health. 'We will use every tool we have to ensure institutions follow the law.' The Trump administration has repeatedly cited antisemitism – especially in the context of contentious pro-Gaza protests on campuses – as a reason to deny promised funds to universities, including Harvard and Columbia. Harvard is fighting the funding decisions in court, while Columbia agreed to a settlement with the government that restored its grants. The funding cut comes days after the Justice Department's Civil Rights Division announced it found UCLA in violation of federal law by 'acting with deliberate indifference in creating a hostile educational environment for Jewish and Israeli students.' While the formal notice to UCLA said the federal government 'now seeks to enter into a voluntary resolution agreement,' Attorney General Pam Bondi sounded less conciliatory. 'DOJ will force UCLA to pay a heavy price for putting Jewish Americans at risk and continue our ongoing investigations into other campuses in the UC system,' Bondi said in a statement. It is not just the Trump administration that has tangled with UCLA over charges of antisemitism. A group of Jewish students filed suit against the university last June, saying the school allowed discrimination against Jews to flourish following Israel's military operation in Gaza in response to the October 7 attacks. The lawsuit said UCLA leaders waited days before responding to a group of pro-Palestinian protesters that refused to allow students to enter campus unless they agreed to 'a statement pledging their allegiance to the activists' views.' UCLA settled the lawsuit earlier this week for $6.45 million, with more than $2 million of the total going to designated 'organizations that combat antisemitism and support the UCLA Jewish community.' UCLA also agreed it is prohibited from 'knowingly allowing or facilitating the exclusion of Jewish students, faculty, and/or staff' from university programs and activities.

Roche's Susvimo maintains vision over five years with two refills per year in people with neovascular age-related macular degeneration (nAMD)
Roche's Susvimo maintains vision over five years with two refills per year in people with neovascular age-related macular degeneration (nAMD)

Yahoo

time4 hours ago

  • Yahoo

Roche's Susvimo maintains vision over five years with two refills per year in people with neovascular age-related macular degeneration (nAMD)

Susvimo is the only continuous delivery treatment to provide reliable, long-term vision outcomes in nAMD, the leading cause of vision loss in people over the age of 60 With two refills per year, Susvimo maintained vision and stabilised the retina for five years, with durability maintained in approximately 95% of patients Susvimo was well tolerated over five years and has a well-characterised safety profile Basel, 01 August 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new, five-year efficacy, safety and durability data from the Phase III Portal study, a long-term extension of the Phase III Archway study, of Susvimo® (ranibizumab injection) for the treatment of people with nAMD.1 Results show that Susvimo's immediate and predictable durability was sustained over five years, with approximately 95% of people receiving treatment every six months requiring no supplemental treatment before each refill. The data were presented at the American Society of Retina Specialists (ASRS) 2025 Annual Meeting in Long Beach, California, United States. 'These long-term results reinforce Susvimo's ability to maintain vision and retinal drying over a long period of time for people with nAMD, the leading cause of vision loss in people over age 60,' said Levi Garraway, MD, PhD, Roche's chief medical officer and head of Global Product Development. 'These robust data reinforce our confidence in Susvimo's unique therapeutic approach, providing an effective alternative to regular eye injections while preserving vision in a sustained manner.' 'People with nAMD often experience suboptimal outcomes with real-world anti-VEGF treatment, largely due to the frequency of injections,' said study investigator John Kitchens, M.D., Retina Associates of Kentucky, who presented the data at ASRS. 'Continuous delivery of treatment with Susvimo may preserve vision in patients with nAMD for longer in real-world clinical use than IVT injections.' In the Portal study (n = 352), people originally treated with Susvimo in Archway continued to receive Susvimo refills every six months (Susvimo cohort; n = 220), while those originally treated with monthly intravitreal (IVT) ranibizumab injections in Archway received Susvimo and then refills every six months (IVT-Susvimo cohort; n = 132). Five-year results showed consistent and sustained disease control and retinal drying in a population who entered Archway with vision at or near peak levels after receiving an average of five intravitreal injections per standard of care. In the Susvimo cohort, best-corrected visual acuity (BCVA) was 74.4 letters at baseline and 67.6 letters at 5 years. In the IVT-Susvimo cohort, BCVA was 76.3 letters at baseline and 68.6 at 5 years. Half of all patients had better than 20/40 vision at five years (Snellen visual acuity test). Average central subfield thickness (CST) remained stable, with a 1.0 (95% CI: -13.1, 11.1) µm reduction from baseline in the Susvimo cohort, and a 10.3 (95% CI: -25.7, 5.0) µm reduction in the IVT-Susvimo cohort. The cohort of people who entered the Portal study from Archway is the largest cohort of people with nAMD to be followed prospectively and continuously for five years in a clinical study.1 Susvimo provides continuous delivery of a customised formulation of ranibizumab via the Port Delivery Platform, while other currently approved treatments may require eye injections as often as once per month. The Port Delivery Platform is a refillable eye implant surgically inserted into the eye during a one-time, outpatient procedure, which introduces medicine directly into the eye, addressing certain retinal conditions that can cause vision loss. About the Archway study and its open-label extension study (Portal)1,2Archway (NCT03677934) was a randomised, multicentre, open-label phase III study evaluating the efficacy and safety of Susvimo refilled every six months at fixed intervals, compared to monthly IVT ranibizumab 0.5 mg in 415 people living with nAMD. Patients were randomized 3:2 to Susvimo (n = 248) or IVT ranibizumab injections (n = 167). Patients enrolled in Archway were responders to prior treatment with anti-VEGF therapy. In both study arms, patients were treated with at least three anti-VEGF injections within the six months prior to their Archway screening visit, with an average of five anti-VEGF injections before randomization. The primary endpoint of the study was the change in BCVA score from baseline at the average of Week 36 and Week 40. Secondary endpoints include safety, overall change in vision (BCVA) from baseline and change from baseline in centre point thickness over time. Patients who completed the study at week 96 were eligible to enter the Portal open-label extension study. In Portal, people originally treated with Susvimo in Archway continued to receive Susvimo refills every six months (Susvimo cohort), while those originally treated with monthly intravitreal (IVT) ranibizumab injections in Archway received the Susvimo implant and then refills every six months (IVT-Susvimo cohort). Portal is ongoing. About neovascular age-related macular degenerationAge-related macular degeneration (AMD) is a condition that affects the part of the eye that provides sharp, central vision needed for activities like reading.3 Neovascular or 'wet' AMD (nAMD) is an advanced form of the disease that can cause rapid and severe vision loss if left untreated.4,5 It develops when new and abnormal blood vessels grow uncontrolled under the macula, causing swelling, bleeding and/or fibrosis.5 Worldwide, around 20 million people are living with nAMD – the leading cause of vision loss in people over the age of 60 – and the condition will affect even more people around the world as the global population ages.3,6,7 About Susvimo® (Port Delivery System with ranibizumab)Approved in the United States by the Food and Drug Administration (FDA) for nAMD, diabetic macular edema (DME) and diabetic retinopathy (DR), Susvimo is a refillable eye implant surgically inserted into the eye during a one-time, outpatient procedure.8,9 Susvimo continuously delivers a customised formulation of ranibizumab over time.8,9 Ranibizumab is a VEGF inhibitor designed to bind to and inhibit VEGF-A, a protein that has been shown to play a critical role in the formation of new blood vessels and the leakiness of the vessels.8-10The customised formulation of ranibizumab delivered by Susvimo is different from the ranibizumab IVT injection, a medicine marketed as Lucentis® (ranibizumab injection)*, which is approved to treat nAMD and other retinal diseases.11 About Roche Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world's largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice. For over 125 years, sustainability has been an integral part of Roche's business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit All trademarks used or mentioned in this release are protected by law. *Lucentis® (ranibizumab injection) was developed by Genentech, a member of the Roche Group. Genentech retains commercial rights in the United States and Novartis has exclusive commercial rights for the rest of the world. References[1] Kitchens J, et al. Five Year Outcomes in nAMD Patients Enrolled in the Archway Study and Treated With the PDS. Presented at: The American Society of Retina Specialists (ASRS) 2025 Annual Meeting; 2025 August 01; Long Beach, California, United States.[2] Regillo C, et al. Archway Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration 2-Year Results. Ophthalmology. 2023;130(7):735-747.[3] Bright Focus Foundation. Age-related macular degeneration (AMD): facts & figures. [Internet; cited July 2025]. Available from: [4] Pennington KL, et al. Epidemiology of AMD: associations with cardiovascular disease phenotypes and lipid factors. Eye and Vision. 2016;3:34.[5] Little K, et al. Myofibroblasts in macular fibrosis secondary to nAMD - the potential sources and molecular cues for their recruitment and activation. EBioMedicine. 2018;38:283-91.[6] Connolly E, et al. Prevalence of AMD associated genetic risk factors and four-year progression data in the Irish population. British Journal of Ophthalmology. 2018 Feb;102:1691-95.[7] Wong WL, et al. Global prevalence of AMD and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. The Lancet Global Health. 2014 Feb;2:106-16.[8] US Food and Drug Administration (FDA). Highlights of prescribing information, Susvimo. 2021. [Internet; cited July 2025]. Available from: [9] Holekamp N, et al. Archway randomised phase III trial of the PDS with ranibizumab for neovascular age-related macular degeneration (nAMD). Ophthalmology. 2021.[10] Heier JS, et al. The angiopoietin/tie pathway in retinal vascular diseases: A review. The Journal of Retinal and Vitreous Diseases. 2021;41:1-19.[11] US FDA. Highlights of prescribing information, Lucentis. 2012. [Internet; cited April 2025]. Available from: [12] US FDA. Highlights of prescribing information, Vabysmo. 2024. [Internet; cited April 2025]. Available from: [13] European Medicines Agency. Summary of product characteristics, Vabysmo. [Internet; cited April 2025]. Available from: Roche Global Media RelationsPhone: +41 61 688 8888 / e-mail: Hans Trees, PhDPhone: +41 79 407 72 58 Sileia UrechPhone: +41 79 935 81 48 Nathalie AltermattPhone: +41 79 771 05 25 Lorena CorfasPhone: +41 79 568 24 95 Simon GoldsboroughPhone: +44 797 32 72 915 Karsten KleinePhone: +41 79 461 86 83 Kirti PandeyPhone: +49 172 6367262 Yvette PetillonPhone: +41 79 961 92 50 Dr Rebekka SchnellPhone: +41 79 205 27 03 Roche Investor Relations Dr Bruno EschliPhone: +41 61 68-75284e-mail: Dr Sabine BorngräberPhone: +41 61 68-88027e-mail: Dr Birgit MasjostPhone: +41 61 68-84814e-mail: Investor Relations North America Loren KalmPhone: +1 650 225 3217e-mail: Attachment Media Investor Release Susvimo Archway study english

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store